CN111195249B - 西达本胺联合r-chop的应用及联合药物 - Google Patents

西达本胺联合r-chop的应用及联合药物 Download PDF

Info

Publication number
CN111195249B
CN111195249B CN201910228406.8A CN201910228406A CN111195249B CN 111195249 B CN111195249 B CN 111195249B CN 201910228406 A CN201910228406 A CN 201910228406A CN 111195249 B CN111195249 B CN 111195249B
Authority
CN
China
Prior art keywords
chop
combined
cell lymphoma
application
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201910228406.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN111195249A (zh
Inventor
鲁先平
赵维莅
付鑫
许彭鹏
刘霆
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ruinjin Hospital Affiliated to Shanghai Jiaotong University School of Medicine Co Ltd
Shenzhen Chipscreen Biosciences Co Ltd
Original Assignee
Ruinjin Hospital Affiliated to Shanghai Jiaotong University School of Medicine Co Ltd
Shenzhen Chipscreen Biosciences Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ruinjin Hospital Affiliated to Shanghai Jiaotong University School of Medicine Co Ltd, Shenzhen Chipscreen Biosciences Co Ltd filed Critical Ruinjin Hospital Affiliated to Shanghai Jiaotong University School of Medicine Co Ltd
Priority to CN202311474046.2A priority Critical patent/CN117797149A/zh
Publication of CN111195249A publication Critical patent/CN111195249A/zh
Application granted granted Critical
Publication of CN111195249B publication Critical patent/CN111195249B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201910228406.8A 2018-11-20 2019-03-25 西达本胺联合r-chop的应用及联合药物 Active CN111195249B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202311474046.2A CN117797149A (zh) 2018-11-20 2019-03-25 西达本胺联合r-chop的应用及联合药物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2018113946147 2018-11-20
CN201811394614 2018-11-20

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202311474046.2A Division CN117797149A (zh) 2018-11-20 2019-03-25 西达本胺联合r-chop的应用及联合药物

Publications (2)

Publication Number Publication Date
CN111195249A CN111195249A (zh) 2020-05-26
CN111195249B true CN111195249B (zh) 2023-11-28

Family

ID=70741744

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201910228406.8A Active CN111195249B (zh) 2018-11-20 2019-03-25 西达本胺联合r-chop的应用及联合药物
CN202311474046.2A Pending CN117797149A (zh) 2018-11-20 2019-03-25 西达本胺联合r-chop的应用及联合药物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202311474046.2A Pending CN117797149A (zh) 2018-11-20 2019-03-25 西达本胺联合r-chop的应用及联合药物

Country Status (11)

Country Link
US (1) US12194054B2 (https=)
EP (1) EP3884943B1 (https=)
JP (1) JP7489397B2 (https=)
CN (2) CN111195249B (https=)
AU (1) AU2019385373B2 (https=)
BR (1) BR112021009627A2 (https=)
MY (1) MY209036A (https=)
PH (1) PH12021551138A1 (https=)
SG (1) SG11202105137RA (https=)
TW (1) TWI768263B (https=)
WO (1) WO2020103788A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN121059617A (zh) * 2020-06-18 2025-12-05 苏州亚盛药业有限公司 包含Bcl-2抑制剂或Bcl-2/Bcl-xL抑制剂的组合产品及其用途
CN112274509B (zh) * 2020-12-02 2022-04-26 四川大学华西医院 西达本胺联合bcl2抑制剂在双表达型b细胞淋巴瘤中的应用
CN121513004B (zh) * 2026-01-14 2026-04-03 首都医科大学附属北京友谊医院 一种治疗abc型弥漫性大b细胞淋巴瘤的组合物及其应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101470112A (zh) * 2007-12-28 2009-07-01 上海交通大学医学院附属瑞金医院 弥漫性大b细胞淋巴瘤治疗指导和预后判断的分子标志物
CN102188415A (zh) * 2003-08-26 2011-09-21 默克Hdac研究有限责任公司 用hdac抑制剂治疗癌症的方法
CN107157978A (zh) * 2017-05-24 2017-09-15 中国药科大学 治疗ebv+dlbcl和dlbcl的药物及组合物
CN108743947A (zh) * 2018-07-04 2018-11-06 复旦大学附属肿瘤医院 一种治疗b细胞淋巴瘤的药物组合物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103833626B (zh) 2012-11-27 2015-11-25 深圳微芯生物科技有限责任公司 西达本胺的晶型及其制备方法与应用
TWI808055B (zh) * 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
IL292457A (en) 2016-07-20 2022-06-01 Univ Columbia Histone acetyl transferase activators, their preparations and their uses

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102188415A (zh) * 2003-08-26 2011-09-21 默克Hdac研究有限责任公司 用hdac抑制剂治疗癌症的方法
CN101470112A (zh) * 2007-12-28 2009-07-01 上海交通大学医学院附属瑞金医院 弥漫性大b细胞淋巴瘤治疗指导和预后判断的分子标志物
CN107157978A (zh) * 2017-05-24 2017-09-15 中国药科大学 治疗ebv+dlbcl和dlbcl的药物及组合物
CN108743947A (zh) * 2018-07-04 2018-11-06 复旦大学附属肿瘤医院 一种治疗b细胞淋巴瘤的药物组合物

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
A Phase II Study of Chidamide Plus R-CHOP in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma: An Interim Analysis;Xu等;《blood》;20171208;第130卷;第4126页"摘要" *
B细胞淋巴瘤之治疗展望;张慕晨等;《中国肿瘤临床》;20160730(第14期);第607-612页 *
周自永等.《新编常用药物手册》.金盾出版社,1998,第755页. *
复发/难治弥漫性大B细胞淋巴瘤治疗进展;张娜等;《临床荟萃》;20171205(第12期);第1027-1036页 *
师丽娜.《实用血液疾病治疗学》.湖北科学技术出版社,2017,第98-100页. *
张克义等.《临床药物不良反应大典》.辽宁科学技术出版社,2001,第423页. *
张宪安等.《全科医生处方手册》.化学工业出版社,2000,第457-458页. *
弥漫大B细胞淋巴瘤治疗最新进展;李静等;《世界最新医学信息文摘》;20180223(第16期);第123-128页 *
弥漫大B细胞淋巴瘤靶向治疗进展;蔡绮纯等;《循证医学》;20160215(第01期);第19-21页 *
西达本胺对不同增殖特性弥漫大B细胞淋巴瘤体外作用机制的研究;张培培等;《中国优秀硕士学位论文全文数据库》;20170215;第1-46页 *

Also Published As

Publication number Publication date
JP2022511126A (ja) 2022-01-28
JP7489397B2 (ja) 2024-05-23
EP3884943C0 (en) 2024-07-17
PH12021551138A1 (en) 2022-02-21
US20220016147A1 (en) 2022-01-20
CN117797149A (zh) 2024-04-02
EP3884943A1 (en) 2021-09-29
AU2019385373B2 (en) 2025-08-21
TW202033194A (zh) 2020-09-16
EP3884943B1 (en) 2024-07-17
SG11202105137RA (en) 2021-06-29
EP3884943A4 (en) 2022-07-06
AU2019385373A1 (en) 2021-06-24
WO2020103788A1 (zh) 2020-05-28
US12194054B2 (en) 2025-01-14
KR20210104059A (ko) 2021-08-24
TWI768263B (zh) 2022-06-21
BR112021009627A2 (pt) 2021-08-10
MY209036A (en) 2025-06-17
CA3120207A1 (en) 2020-05-28
CN111195249A (zh) 2020-05-26

Similar Documents

Publication Publication Date Title
AU2012321110B2 (en) Combination treatment
Munakata et al. Phase 1 study of tazemetostat in Japanese patients with relapsed or refractory B‐cell lymphoma
Bracarda et al. Could interferon still play a role in metastatic renal cell carcinoma? A randomized study of two schedules of sorafenib plus interferon-alpha 2a (RAPSODY)
CN111195249B (zh) 西达本胺联合r-chop的应用及联合药物
Wilber et al. Chemoprophylaxis for Pneumocystis carinii pneumonitis: outcome of unstructured delivery
KR20230136603A (ko) S1p 수용체 조정제를 사용한 치료 방법
WO2021160147A1 (zh) 吡啶并[1,2-a]嘧啶酮化合物的治疗淋巴瘤的用途
US20190240242A1 (en) Combination treatment of acute myeloid leukemia and myelodysplastic syndrome ii
RU2802620C2 (ru) Применение хидамида в комбинации с R-CHOP и комбинация лекарственных средств
JP6708634B2 (ja) 急性骨髄性白血病及び骨髄異形成症候群の併用療法ｉｉｉ
CA3120207C (en) Application of chidamide in combination with r-chop, and drug combination
KR102958344B1 (ko) R-chop와 병용되는 치다마이드의 활용 및 약물 조합
CN102327599A (zh) 用于治疗骨髓增生异常综合征的组合物和方法
CN111195250A (zh) 西达本胺联合dice的应用及联合药物
CN111228264A (zh) 西达本胺联合cgb以及自体造血干细胞的应用及联合药物
CN116723835A (zh) 使用s1p受体调节剂的治疗方法
Smith et al. Novel pharmaceuticals and therapeutics for tumor necrosis factor-alpha-resistant Crohn's disease: A narrative review
HK40057612A (en) Application of chidamide in combination with r-chop, and drug combination
HK40057612B (en) Application of chidamide in combination with r-chop, and drug combination
JP6643978B2 (ja) 頭頚部がんの処置または予防において使用されるｐｉ３キナーゼ阻害剤とパクリタキセルの組合せ
CN113925865A (zh) 安罗替尼联合免疫检查点抑制剂治疗晚期肺癌的增效组合药物
Anticoagulation NEW DRUG APPROVALS
Kochi et al. Efficacy of low-dose thiopurine therapy for the induction of remission in steroid-dependent ulcerative colitis: Comparison with cytapheresis
MX2011009301A (es) Composiciones y metodos para tratar sindrome mielodisplasico.

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant